Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome

Yuko Yamagishi, Motoi Kuwahara, Hidekazu Suzuki, Masahiro Sonoo, Satoshi Kuwabara, Takanori Yokota, Kyoichi Nomura, Atsuro Chiba, Ryuji Kaji, Takashi Kanda, Ken Ichi Kaida, Tatsuro Mutoh, Ryo Yamasaki, Hiroshi Takashima, Makoto Matsui, Kazutoshi Nishiyama, Gen Sobue, Susumu Kusunoki

研究成果: ジャーナルへの寄稿学術論文査読

13 被引用数 (Scopus)


Objective Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool. Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. Methods The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. Results The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. Conclusions The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes.

ジャーナルJournal of Neurology, Neurosurgery and Psychiatry
出版ステータス出版済み - 01-12-2020

All Science Journal Classification (ASJC) codes

  • 外科
  • 臨床神経学
  • 精神医学および精神衛生


「Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。